Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Now Rated “Buy” by Wall Street Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have earned an average rating of “Buy” from the thirteen research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and three have given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $63.40.

Several research analysts have recently weighed in on the company. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th.

Maze Therapeutics Stock Performance

MAZE opened at $26.43 on Thursday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -10.49 and a beta of 2.16. Maze Therapeutics has a 12 month low of $21.95 and a 12 month high of $53.65. The firm’s fifty day simple moving average is $26.93 and its 200 day simple moving average is $27.89. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, research analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the sale, the chief executive officer directly owned 18,151 shares in the company, valued at approximately $477,189.79. The trade was a 65.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider directly owned 26,250 shares in the company, valued at $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 192,991 shares of company stock valued at $5,152,084. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. lifted its stake in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after acquiring an additional 465,641 shares during the last quarter. TRV GP IV LLC acquired a new stake in Maze Therapeutics in the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics during the second quarter worth about $122,983,582. BlackRock Inc. bought a new position in Maze Therapeutics during the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC acquired a new position in Maze Therapeutics during the second quarter worth approximately $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.